Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02708680 · ClinicalTrials.gov registry record · Phase 1
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
A Phase 1 study, sponsored by Syndax Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 89
- Enrollment target
NCT02708680 is a Phase 1 study that has completed, run by Syndax Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT02708680, a Phase 1 study, has completed, sponsored by Syndax Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC). Additionally, the purpose of the study is to assess how effective entinostat and atezolizumab are in combination in participants with aTNBC.
Interventions
- DRUG Placebo
- DRUG Atezolizumab
- DRUG Entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02708680
The ClinicalTrials.gov registry entry for NCT02708680 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02708680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02708680 about?
NCT02708680 is a clinical study titled "Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In". The purpose of this study is to determine the safety and tolerability of entinostat used in combination with atezolizumab in participants with Advanced Triple Negative Breast Cancer (aTNBC). Additionally, the purpose of the study is to assess how effective entinostat and atezolizumab are in combinat...
What is the current status of trial NCT02708680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 89 participants. The study started on 2016-05. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT02708680?
The interventions under investigation include: Placebo (DRUG), Atezolizumab (DRUG), Entinostat (DRUG).
Who is sponsoring clinical trial NCT02708680?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.